About Tiffany D. Rau

Tiffany D Rau, Ph.D., Owner and Principal Consultant of Rau Consulting and is an expert in bio processing and a Six Sigma Master Black Belt. Her international technical and managerial experience extends from development to post-commercial cGMP manufacturing. Dr. Rau has been instrumental in designing and leading initiatives to bring R&D and manufacturing together to increase speed to market and minimize technology transfer challenges. Dr. Rau has been the advisor on over 100 different projects in the areas of process intensification, scale-up, variability reduction, and continuous improvement for both mammalian and microbial expression systems.  

Previously, Dr. Rau has held leadership positions at Evonik-Degussa, Eli Lilly, Pall and GlaxoSmithKline all focused in process development, tech transfer, commercial manufacturing, and CMC strategy. Dr. Rau has over 75 invited speaking engagements focused on delivering current and next-generation products from R and D to commercialization/post-commercialization. Tiffany is also active in the scientific community and is Program Chair for the Recent Advances in Fermentation Technology meeting (2015-2019) and has organized numerous sessions at the SIMB National Meetings (Society of Industrial Microbiology and Biotechnology) and ECI Cell Culture Engineering meetings. She was also part of the inaugural organizing team for ECI’s Microbial Engineering Conference in 2018 and continued on the organizing committee for 2020.

Tiffany is involved in academia and was part of the University of Pennsylvania’s Capstone engineering program for many years as well as Vanderbilt University’s Capstone program where she was the first industrial participant. She is also on Vanderbilt’s Chemical and Biomolecular Engineering External Advisory Board. Her students' work in the past has focused on designing manufacturing facilities for biotechnology processes, for example, regenerative medicine, cell therapies, MAbs, and vaccines. AICHE’s National Design Competition Committee is chaired by Tiffany and she is part of the organizing committee for ACS/ESBES International Biotechnology Design Competition. She is also an editor of the Journal of Industrial Microbiology and Biotechnology (JIMB) – Special Issues. Tiffany earned her BSE degree in Chemical and Bio molecular Engineering from the University of Pennsylvania and her Ph.D. in Chemical Engineering from Vanderbilt University.

photo of Tiffany D Rau  Biotech Consultant

Tiffany D. Rau Ph. D

Founder and Principal Consultant
Tiffany - Linked In »


Tiffany Rau at BPI Boston


Proven experience in setting up development and manufacturing centers of excellence in a global environment.

Human health and animal health and the scientific and regulatory environment 

Process development in industrial biotechnology.

Process robustness and reduction of variability ie Design for Manufacturing and DoE

Bioreactor development for microbial and mammalian cell culture.

Pilot plant design and management built to cGMP specifications- Projects greater than $6 million

Multiple biological products currently on market including the 1st Bio similar Insulin (Tech Transfer) and At Scale "Development"​ and commercial launch material

International process "development"​ consulting in bio pharmaceuticals, vaccines, and industrial biotechnology 
Process Improvements/Optimization and process robustness.

Global scientific and business development/relationship management.

Development and Integration of "new" technology into organizations.

External Manufacturing and development management Improving product titers using small molecule additives while extending culture viability.

Creation of well plate-based cell culture assays for increasing the speed of testing and evaluating in vitro cell cultures and conditions.

Connecting MAb production enhancement to the biochemical network for specific productivity.

Laboratory and IT project management

CDMO Management  




Biotech consultant  providing strategic solutions and expertise to guide you through the challenges associated with: 
- Late Discovery, Early Development 
- Late Development/Commercialization
- Regulatary Submission to Approval
across all the essential drug development workstreams.


Rau Consulting, LLC

Email: info@raubiotech.com